CHO Pharma Past Earnings Performance
Past criteria checks 0/6
CHO Pharma has been growing earnings at an average annual rate of 2.7%, while the Pharmaceuticals industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 17.7% per year.
Key information
2.7%
Earnings growth rate
3.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | 17.7% |
| Return on equity | -10.3% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How CHO Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -306 | 30 | 239 |
| 30 Sep 23 | 0 | -317 | 27 | 277 |
| 30 Jun 23 | 0 | -327 | 24 | 315 |
| 31 Mar 23 | 0 | -333 | 24 | 321 |
| 31 Dec 22 | 0 | -338 | 25 | 326 |
| 30 Sep 22 | 2 | -298 | 24 | 284 |
| 30 Jun 22 | 4 | -257 | 23 | 242 |
| 31 Mar 22 | 4 | -232 | 22 | 218 |
| 31 Dec 21 | 4 | -206 | 20 | 194 |
| 30 Sep 21 | 2 | -223 | 21 | 212 |
| 30 Jun 21 | 0 | -240 | 21 | 230 |
| 31 Mar 21 | 0 | -269 | 21 | 259 |
| 31 Dec 20 | 0 | -297 | 22 | 288 |
| 30 Sep 20 | 0 | -328 | 23 | 317 |
| 30 Jun 20 | 0 | -359 | 24 | 347 |
| 31 Mar 20 | 0 | -359 | 24 | 346 |
| 31 Dec 19 | 0 | -358 | 25 | 345 |
| 30 Sep 19 | 0 | -347 | 24 | 335 |
| 30 Jun 19 | 0 | -337 | 23 | 325 |
| 31 Mar 19 | 0 | -322 | 23 | 311 |
| 31 Dec 18 | 0 | -307 | 22 | 297 |
| 30 Sep 18 | 0 | -309 | 27 | 295 |
| 30 Jun 18 | 0 | -312 | 32 | 294 |
| 31 Mar 18 | 0 | -310 | 34 | 291 |
| 31 Dec 17 | 0 | -309 | 35 | 289 |
| 30 Sep 17 | 1 | -293 | 32 | 276 |
| 30 Jun 17 | 1 | -278 | 30 | 264 |
| 31 Mar 17 | 1 | -262 | 25 | 254 |
| 31 Dec 16 | 2 | -245 | 21 | 243 |
| 30 Sep 16 | 1 | -203 | 14 | 211 |
| 30 Jun 16 | 1 | -161 | 7 | 178 |
| 31 Mar 16 | 0 | -135 | 3 | 160 |
| 31 Dec 15 | 0 | -110 | 0 | 141 |
Quality Earnings: 6586 is currently unprofitable.
Growing Profit Margin: 6586 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6586 is unprofitable, but has reduced losses over the past 5 years at a rate of 2.7% per year.
Accelerating Growth: Unable to compare 6586's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6586 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-15%).
Return on Equity
High ROE: 6586 has a negative Return on Equity (-10.29%), as it is currently unprofitable.